Provided by Tiger Trade Technology Pte. Ltd.

Cogent

19.00
+1.116.20%
Post-market: 19.250.2500+1.32%18:44 EST
Volume:1.96M
Turnover:37.43M
Market Cap:933.30M
PE:-4.67
High:19.50
Open:17.93
Low:17.84
Close:17.89
52wk High:84.06
52wk Low:15.96
Shares:49.12M
Float Shares:47.97M
Volume Ratio:0.96
T/O Rate:4.09%
Dividend:4.03
Dividend Rate:21.19%
EPS(TTM):-4.0643
EPS(LYR):-4.2848
ROE:-136.94%
ROA:-2.47%
PB:-23.83
PE(LYR):-4.43

Loading ...

Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13

MT Newswires Live
·
Nov 11

Cogent Biosciences Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Nov 11

U.S. Small Caps Move Upward; Cogent Biosciences Leads Increases

Dow Jones
·
Nov 11

Cogent announces $200M convertible senior notes, $200M common stock offerings

TIPRANKS
·
Nov 11

Press Release: Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Dow Jones
·
Nov 11

Cogent Biosciences: Promising Outlook with Breakthrough GIST Treatment and Strategic Growth Plans

TIPRANKS
·
Nov 11

Cogent Biosciences’ Bezuclastinib Shows Promising Phase 3 Results, Boosting Buy Rating and Price Target

TIPRANKS
·
Nov 11

Cogent Biosciences price target raised to $50 from $18 at Leerink

TIPRANKS
·
Nov 11

Cogent Biosciences rises 135.0%

TIPRANKS
·
Nov 11

Cogent Biosciences’ Phase 3 PEAK Study Success Positions Company for Market Leadership and $1.1 Billion Peak Sales

TIPRANKS
·
Nov 11

Cogent Biosciences upgraded to Buy from Hold at Stifel

TIPRANKS
·
Nov 11

Cogent Biosciences upgraded to Outperform from Neutral at Wedbush

TIPRANKS
·
Nov 10

Cogent Biosciences Shares Double On Tumor Drug Positive Trial Results

Dow Jones
·
Nov 10

Cogent Biosciences reports data from Phase 3 PEAK trial of bezuclastinib

TIPRANKS
·
Nov 10

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
Nov 10

Cogent Communications Shares Fall After UBS, Wells Fargo Downgrades

MT Newswires Live
·
Nov 08

Mizuho Securities downgrades Cogent Comms (CCOI) to a Hold

TIPRANKS
·
Nov 08

UBS Downgrades Cogent Communications to Neutral From Buy, Cuts Price Target to $27 From $50

MT Newswires Live
·
Nov 07

Cogent Communications Holdings Inc : UBS Cuts to Neutral From Buy

THOMSON REUTERS
·
Nov 07

Stock Track | Cogent Communications Plunges 5.41% Pre-Market on Multiple Analyst Downgrades

Stock Track
·
Nov 07